

**REMARKS**

Claims 13-16, 21-23, 25-30, 35-37 and 41-46 are allowed.

The amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. They correct (i) a lack of antecedent basis for “polypeptide” in claim 27 and (ii) inconsistency between claim 37 and claims 21/30. Entry of the amendments is requested to correct these informalities. Applicants submit the amendments do not change the scope of the claims allowed by the Examiner.

Applicants submit that the claims remain allowable for the reasons of record. Early issuance of this patent is earnestly solicited. The Examiner is invited to contact the undersigned if additional information is required.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:                     /Gary R. Tanigawa/                      
Gary R. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100